Influencing factors affecting the outcome of prostate biopsy in patients with prostate-specific antigen in grey area

HUANG Denghui; ZHOU Guangchen

doi:10.7619/jcmp.20231254

Journal of Clinical Medicine in Practice > 2023 > 27(15): 77-81. > DOI: 10.7619/jcmp.20231254

HUANG Denghui, ZHOU Guangchen. Influencing factors affecting the outcome of prostate biopsy in patients with prostate-specific antigen in grey area[J]. Journal of Clinical Medicine in Practice, 2023, 27(15): 77-81. DOI: 10.7619/jcmp.20231254

Citation:

PDF (839 KB)

Influencing factors affecting the outcome of prostate biopsy in patients with prostate-specific antigen in grey area

HUANG Denghui^{1, 2},
ZHOU Guangchen^1, ,

1.
Department of Urinary Surgery, Jiangsu North Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225000
2.
Department of Urinary Surgery, Wenshang County People's Hospital of Shandong Province, Jining, Shandong, 272500

More Information

Received Date: April 18, 2023
Revised Date: May 15, 2023
Available Online: September 03, 2023

Graphical Abstract

Abstract

Abstract

Objective
To investigate the influencing factors in diagnosis of prostate cancer by performing prostate puncture biopsy in patients with prostate specific antigen (PSA) in gray area.
Methods
The medical records of patients undergoing transrectal ultrasound-guided prostate biopsy in Jiangsu North Hospital Affiliated to Yangzhou University from January 2020 to February 2022 were retrospectively collected. According to the inclusion and exclusion criteria, a total of 221 patients were included in the study, including 148 patients with negative puncture results and 73 patients with prostate cancer, with the detection rate of 33.03%. Univariate and multivariate analysis were performed for age, the free PSA to total PSA ratio (f/t PSA), prostate volume, PSAD and other parameters to explore the independent influencing factors of prostate cancer.
Results
Univariate analysis showed that there were statistically significant differences in age, PSAD, f/t PSA, nuclear magnetic examination and prostate volume in prostate cancer patients when compared with those of negative results. Binary Logistic regression analysis showed that age, PSAD and prostate MRI were independent influencing factors for prostate cancer (P < 0.05), but there was no significant difference in prostate volume and f/t PSA (P>0.05). Receiver operating characteristic (ROC) curve analysis showed that the area under the curves of age, PSAD, prostate MRI, age combined with PSAD, age combined with prostate MRI, PSAD combined with prostate MRI, and age combined with PSAD as well as prostate MRI were 0.619, 0.806, 0.653, 0.804, 0.709, 0.831 and 0.843, respectively.
Conclusion
For patients with PSA in gray area who underwent puncture biopsy of prostate gland, the independent risk factors for prostate cancer diagnosis are age, PSAD and prostate MRI, among which PSAD has higher value in diagnosis. Age combined with PSAD as well as prostate MRI is more helpful to guide the clinical need for further prostate biopsy.

FullText(HTML)

References (21)

References

[1]	DANIYAL M, SIDDIQUI Z A, AKRAM M, et al. Epidemiology, etiology, diagnosis and treatment of prostate cancer[J]. Asian Pac J Cancer Prev, 2014, 15(22): 9575-9578. doi: 10.7314/APJCP.2014.15.22.9575
[2]	TORRE L A, SIEGEL R L, WARD E M, et al. Global cancer incidence and mortality rates and trends: an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27. doi: 10.1158/1055-9965.EPI-15-0578
[3]	曾柯, 谢文贤, 杨键, 等. 血清游离前列腺特异性抗原对良性前列腺增生患者预后的评估价值探讨[J]. 实用临床医药杂志, 2022, 26(5): 39-43. doi: 10.7619/jcmp.20212093
[4]	TAN G H, NASON G, AJIB K, et al. Smarter screening for prostate cancer[J]. World J Urol, 2019, 37(6): 991-999. doi: 10.1007/s00345-019-02719-5
[5]	DEARNALEY D, HINDER V, HIJAB A, et al. Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(4): 501-513. doi: 10.1016/S1470-2045(22)00092-4
[6]	HAN Y Y, SONG J Y, TALBOTT E O. Serum folate and prostate-specific antigen in the United States[J]. Cancer Causes Control, 2013, 24(8): 1595-1604. doi: 10.1007/s10552-013-0236-7
[7]	WANG Z T, CHAN M T, TSANG W C, et al. Utility of serum biomarkers for predicting cancer in patients with previous negative prostate biopsy[J]. World J Urol, 2022, 40(9): 2255-2260. doi: 10.1007/s00345-022-04085-1
[8]	CHEN M, MA T, LI J, et al. Diagnosis of prostate cancer in patients with prostate-specific antigen (PSA) in the gray area: construction of 2 predictive models[J]. Med Sci Monit, 2021, 27: e929913.
[9]	王涛. PI-RADS评分1-3分患者首次前列腺穿刺活检术中诊断前列腺癌的危险因素分析[D]. 沈阳: 中国医科大学, 2021.
[10]	FOLEY R W, GORMAN L, SHARIFI N, et al. Improving multivariable prostate cancer risk assessment using the Prostate Health Index[J]. BJU Int, 2016, 117(3): 409-417. doi: 10.1111/bju.13143
[11]	AN J Y, HARMON S A, MEHRALIVAND S, et al. Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15mm the best threshold[J]. Abdom Radiol, 2018, 43(12): 3436-3444. doi: 10.1007/s00261-018-1631-z
[12]	CHANG Y F, CHEN R, YANG Q S, et al. Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality[J]. Oncotarget, 2017, 8(21): 34836-34843. doi: 10.18632/oncotarget.16753
[13]	LI X E, LI C M, CHEN M. Patients with "gray zone" PSA levels: application of prostate MRI and MRS in the diagnosis of prostate cancer[J]. Magnetic Resonance Imaging, 2023, 57(4): 992-1010. doi: 10.1002/jmri.28505
[14]	LIU C, LIU S L, WANG Z X, et al. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment[J]. Asian J Androl, 2018, 20(5): 459-464. doi: 10.4103/aja.aja_19_18
[15]	LI Y, MONGAN J, BEHR S C, et al. Beyond prostate adenocarcinoma: expanding the differential diagnosis in prostate pathologic conditions[J]. Radiographics, 2016, 36(4): 1055-1075. doi: 10.1148/rg.2016150226
[16]	STEPHAN C, SCHNORR D, LOENING S A, et al. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/mL: systematic review and meta-analysis[J]. Eur Urol, 2005, 48(6): 1059-1060. doi: 10.1016/j.eururo.2005.08.011
[17]	SHAN J H, LIU Z Y, GENG X Y, et al. The influence of age on prostate cancer screening index[J]. J Clin Lab Anal, 2022, 36(1): e24098. doi: 10.1002/jcla.24098
[18]	SATIROGLU O, BOSTAN M, UZUN H, et al. Severity of coronary artery disease and prostate-specific antigen relationship in men[J]. Eur Rev Med Pharmacol Sci, 2012, 16(15): 2078-2081.
[19]	OMRI N, KAMIL M, ALEXANDER K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume[J]. Prostate, 2020, 80(16): 1444-1449. doi: 10.1002/pros.24078
[20]	时新宇, 裴昕奇, 樊俊杰, 等. MRI阴性患者前列腺穿刺活检阳性的相关危险因素分析及预测模型的建立[J]. 现代泌尿外科杂志, 2021, 26(2): 139-142. https://www.cnki.com.cn/Article/CJFDTOTAL-MNWK202102012.htm
[21]	王哲, 王勤章, 钱彪, 等. 石河子地区前列腺穿刺活检阳性的相关危险因素分析及预测模型的建立[J]. 中国老年学杂志, 2019, 39(24): 6020-6023. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201924041.htm

Cited By

Get Citation

PDF

XML

Article views (123) PDF downloads (6)

Turn off MathJax

Article Contents

Abstract

References

Influencing factors affecting the outcome of prostate biopsy in patients with prostate-specific antigen in grey area

Abstract

References

Catalog

Export File

Citation

Format

Content